Shares of Halozyme Therapeutics (HALO, Financial) experienced a significant increase, rising by 5.02% to reach $61.08. The trading volume was recorded at 858,272 shares, with a turnover rate of 0.68% and a price fluctuation of 5.87%.
Recent financial reports show the company achieved a revenue of $231 million, a net profit of $93.25 million, and earnings per share of $0.73. The gross profit stood at $174 million, with a price-to-earnings ratio of 23.64.
Analyst ratings from 11 firms indicated that 55% recommended buying the stock, while 45% suggested holding, with no ratings to sell.
Within the biotechnology sector, where Halozyme operates, the overall decline was 1.79%. However, notable stock performance was observed in companies like Elevai Labs, Inc., Theriva Biologics, Inc., and Transcode Therapeutics, Inc. Theriva Biologics, Inc., Aditxt, Inc., and Elevai Labs, Inc. showed high turnover rates, at 5386.48%, 1604.61%, and 962.82% respectively. Stocks with significant price fluctuations included Psyence Biomedical Ltd, Elevai Labs, Inc., and Seastar Medical Holding Corp, with amplitudes of 142.28%, 63.50%, and 55.45% respectively.
Halozyme Therapeutics is a biotechnology firm focused on developing and commercializing innovative cancer therapies. The company aims to create treatments targeting human enzymes that alter tumors. Halozyme prioritizes unmet medical needs in oncology, licensing its technology to biopharmaceutical firms for joint product development. Based in the U.S., Halozyme has limited long-term assets internationally.
